High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast

Papillary lesions of the breast have an uncertain relationship to the histogenesis of breast carcinoma, and are thus diagnostically and managerially challenging. Molecular genetic studies have provided evidence that ductal carcinoma in situ and even atypical ductal hyperplasia are precursors of invasive carcinoma. However, papillary lesions have been seldom studied. We screened papillary breast neoplasms for activating point mutations in PIK3CA, AKT1, and RAS protein-family members, which are common in invasive ductal carcinomas. DNA extracts were prepared from sections of 89 papillary lesions, including 61 benign papillomas (28 without significant hyperplasia; 33 with moderate to florid hyperplasia), 11 papillomas with atypical ductal hyperplasia, 7 papillomas with carcinoma in situ, and 10 papillary carcinomas. Extracts were screened for PIK3CA and AKT1 mutations using mass spectrometry; cases that were negative were further screened for mutations in AKT2, BRAF, CDK, EGFR, ERBB2, KRAS, NRAS, and HRAS. Mutations were confirmed by sequencing or HPLC assay. A total of 55 of 89 papillary neoplasms harbored mutations (62%), predominantly in AKT1 (E17K, 27 cases) and PIK3CA (exon 20 >exon 9, 27 cases). Papillomas had more mutations in AKT1 (54%) than in PIK3CA (21%), whereas papillomas with hyperplasia had more PIK3CA (42%) than AKT1 (15%) mutations, as did papillomas with atypical ductal hyperplasia (PIK3CA 45%, AKT1 27%, and NRAS 9%). Among seven papillomas with carcinoma in situ, three had AKT1 mutations. The 10 papillary carcinomas showed an overall lower frequency of mutations, including 1 with an AKT1 mutation (in a tumor arising from a papilloma), 1 with an NRAS gene mutation (Q61H), and 2 with PIK3CA mutations (1 overlapping with the NRAS Q61H). These findings indicate that approximately two-thirds of papillomas are driven by mutations in the PI3CA/AKT pathway. Some papillary carcinomas may arise from these lesions, but others may have different molecular origins.

[1]  T. Aihara,et al.  Clonal analysis of benign and malignant human breast tumors by means of polymerase chain reaction. , 1995, Cancer letters.

[2]  L. Skoog,et al.  PIK3CA Mutations and PTEN Loss Correlate with Similar Prognostic Factors and Are Not Mutually Exclusive in Breast Cancer , 2007, Clinical Cancer Research.

[3]  S. Lakhani,et al.  Comparative genomic hybridization analysis of bilateral hyperplasia of usual type of the breast , 2003, The Journal of pathology.

[4]  G. Bevilacqua,et al.  Papillary lesions of the breast: a molecular progression? , 2005, Breast Cancer Research and Treatment.

[5]  H. Koyama,et al.  Diagnosis of ductal carcinoma in situ (DCIS) and intraductal papilloma using fluorescence in Situ Hybridization (FISH) analysis , 2000, Breast cancer.

[6]  J. Ptak,et al.  High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.

[7]  L. Collins,et al.  Papillary lesions of the breast: selected diagnostic and management issues , 2007, Histopathology.

[8]  M. Monden,et al.  Clinicopathologic Analysis of Breast Cancers with PIK3CA Mutations in Japanese Women , 2007, Clinical Cancer Research.

[9]  D. Sgroi,et al.  Re-evaluating early breast neoplasia , 2008, Breast Cancer Research.

[10]  A. Marchetti,et al.  AKT1E17K in human solid tumours , 2008, Oncogene.

[11]  S. Lakhani,et al.  Molecular evolution of breast cancer , 2005, The Journal of pathology.

[12]  Suk Woo Nam,et al.  PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas , 2005, Oncogene.

[13]  S. Fuqua,et al.  Histological and biological evolution of human premalignant breast disease. , 2001, Endocrine-related cancer.

[14]  R. Salunga,et al.  Gene expression profiles of human breast cancer progression , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[15]  S. Lakhani,et al.  The diagnosis and management of pre-invasive breast disease: Genetic alterations in pre-invasive lesions , 2003, Breast Cancer Research.

[16]  M. Salto‐Tellez,et al.  Mutational hotspot in Exon 20 of PIK3CA in breast cancer among singapore chinese , 2006, Cancer biology & therapy.

[17]  H. Höfler,et al.  20q13.2 Amplification in intraductal hyperplasia adjacent to in situ and invasive ductal carcinoma of the breast , 1999, Virchows Archiv.

[18]  S. H. Lee,et al.  Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias , 2008, British Journal of Cancer.

[19]  B. Iacopetta,et al.  PIK3CA mutations in breast cancer are associated with poor outcome , 2006, Breast Cancer Research and Treatment.

[20]  M. Wymann,et al.  Phosphoinositide 3-kinase in disease: timing, location, and scaffolding. , 2005, Current opinion in cell biology.

[21]  Hanina Hibshoosh,et al.  PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. , 2005, Cancer research.

[22]  Y. Samuels,et al.  Oncogenic mutations of PIK3CA in human cancers. , 2004, Current topics in microbiology and immunology.

[23]  S. Devries,et al.  Genetic changes in paired atypical and usual ductal hyperplasia of the breast by comparative genomic hybridization. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  A. Gerdes,et al.  Chromosome abnormalities in benign hyperproliferative disorders of epithelial and stromal breast tissue , 1995, International journal of cancer.

[25]  M. Troxell,et al.  Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma , 2010, Breast Cancer Research and Treatment.

[26]  S. Hirohashi,et al.  Detection of numerical alterations of chromosomes 3, 7, 17 and X in low-grade intracystic papillary tumors of the breast by multi-color fluorescencein situ hybridization , 1997, Breast cancer.

[27]  H. Koyama,et al.  Clonal analysis of solitary intraductal papilloma of the breast by means of polymerase chain reaction. , 1994, The American journal of pathology.

[28]  J. Rosai.  Papillary carcinoma. , 1993, Monographs in pathology.

[29]  William Pao,et al.  Genetic predictors of MEK dependence in non-small cell lung cancer. , 2008, Cancer research.

[30]  R. Elledge,et al.  Premalignant and In Situ Breast Disease: Biology and Clinical Implications , 2005, Annals of Internal Medicine.

[31]  W. Muller,et al.  The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer , 2007, Oncogene.

[32]  D. Page,et al.  Combined histologic and cytologic criteria for the diagnosis of mammary atypical ductal hyperplasia. , 1992, Human pathology.

[33]  H. Thornton,et al.  Ductal carcinoma-in-situ of the breast , 1992, The Lancet.

[34]  T. Kawabe,et al.  Functional analysis of PIK3CA gene mutations in human colorectal cancer. , 2005, Cancer research.

[35]  Roger J. Daly,et al.  The Ras Signaling Pathway in Mammary Tumorigenesis and Metastasis , 2004, Journal of Mammary Gland Biology and Neoplasia.

[36]  Yong Yu,et al.  Analysis of the progression of intraductal proliferative lesions in the breast by PCR-based clonal assay , 2009, Breast Cancer Research and Treatment.

[37]  G. MacGrogan,et al.  LOH at 16p13 is a novel chromosomal alteration detected in benign and malignant microdissected papillary neoplasms of the breast. , 1998, Human pathology.

[38]  Zhi Hu,et al.  An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. , 2008, Cancer research.

[39]  H. Höfler,et al.  Accumulation of chromosomal imbalances from intraductal proliferative lesions to adjacent in situ and invasive ductal breast cancer. , 2000, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[40]  J. Engelman,et al.  Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. , 2005, Cancer research.

[41]  P. O’Connell,et al.  Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. , 1998, Journal of the National Cancer Institute.

[42]  Hiroyuki Konishi,et al.  The PIK3CA gene is mutated with high frequency in human breast cancers , 2004, Cancer biology & therapy.

[43]  F. Koerner,et al.  Solid papillary carcinoma of the breast. A form of intraductal carcinoma with endocrine differentiation frequently associated with mucinous carcinoma. , 1995, The American journal of surgical pathology.

[44]  Spyro Mousses,et al.  A transforming mutation in the pleckstrin homology domain of AKT1 in cancer , 2007, Nature.

[45]  Robert A. Weinberg,et al.  Ras oncogenes: split personalities , 2008, Nature Reviews Molecular Cell Biology.

[46]  Yiling Lu,et al.  Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery , 2005, Nature Reviews Drug Discovery.

[47]  A. Mulligan,et al.  Papillary Lesions of the Breast: A Review , 2007, Advances in anatomic pathology.

[48]  P. V. van Diest,et al.  Ductal epithelial proliferations of the breast: a biological continuum? Comparative genomic hybridization and high‐molecular‐weight cytokeratin expression patterns , 2001, The Journal of pathology.

[49]  L. Zhao,et al.  Class I PI3K in oncogenic cellular transformation , 2008, Oncogene.